Loading...
•
Sep 30, 2021
Theravance Q3 2021 Earnings Report
Reported third quarter financial results and provided a business update.
Key Takeaways
Theravance Biopharma reported their Q3 2021 financial results, highlighting their strategic plan execution to become cash-flow positive by the second half of 2022, focusing on YUPELRI growth, R&D streamlining, and portfolio optimization.
Executing strategy to create a new Theravance Biopharma, focused on respiratory therapeutics.
On track to reduce headcount by approximately 75%.
Focusing on driving growth of YUPELRI.
Streamlining R&D investment and optimizing asset portfolio to maximize shareholder value.
Theravance
Theravance
Forward Guidance
Theravance Biopharma expects the effects of COVID-19 to continue to adversely impact business operations and financial results, the extent of the impact on our ability to generate revenue from YUPELRI® (revefenacin), our clinical development programs, and the value of and market for our ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time.
Challenges Ahead
- The ultimate duration of the COVID-19 pandemic.
- Travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries.
- Other measures taken by us and those we work with to help protect individuals from contracting COVID-19.
- The effectiveness of actions taken globally to contain and treat the disease, including vaccine availability, distribution, acceptance and effectiveness.